Compare FirstEnergy Corp. (FE) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Cassava Sciences Inc — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.95B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: FirstEnergy Corp. is far larger — about 658.6× Cassava Sciences Inc's market cap, and FirstEnergy Corp. pays a 4.15% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Cassava Sciences Inc for 37 Days on average.
| FE | FLNA | |
|---|---|---|
Market Cap | $25.95B | $39.40M |
Volume | 5,643,833 | 759,018 |
Sector | Utilities | Health |
52-Week High | $51.91 | $4.64 |
52-Week Low | $43.04 | $0.68 |
Typical Hold Time | 71 Days | 37 Days |
Enterprise Value | $54.87B | -$43.28M |
Dividend Yield | 4.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% today, with a bullish technical signal but mixed earnings history. Revenue grew to $15.09B in 2025, with a net income margin of 6.86%, while valuation ratios like P/E of 23.84 and P/S of 1.63 suggest moderate pricing. Recent news highlights dividend declarations and a $36B Energize365 investment plan, supporting long-term growth amid rising data-center demand.
Outlook is positive with a consensus price target of $52.80, implying 18% upside, but risks include high debt levels and volatile cash flows. Analyst sentiment is mixed with 43% buy ratings, while institutional ownership trends show recent stake increases, indicating cautious optimism for steady utility returns.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
